Genetic testing showed that people who carry the CYP2B6*6 gene variation are more likely to benefit from the smoking-cessation drug bupropion than those who do not have the gene variation, a new study found. Researchers hope genetic testing could help doctors recommend the best treatments to individuals who want to quit smoking.

Related Summaries